JNCI Cancer Spectrum最新文献

{"title":"Comparing chemotherapy-induced nausea and vomiting between young adult vs non-young adult cancer patients.","authors":"Laura B Oswald, Aasha I Hoogland, Taylor L Welniak, Oanh L Nguyen, Yvelise Rodriguez, Xiaoyin Li, Samantha Reese, Paige W Lake, Brian D Gonzalez, Martine Extermann, Jonathan Metts, Matthew A Murphy, Brent J Small, Donna L Berry, Daneng Li, Kristen M Carpenter, Stacy M Fischer, Anita Y Kinney, Heather S L Jim","doi":"10.1093/jncics/pkag082","DOIUrl":"10.1093/jncics/pkag082","url":null,"abstract":"<p><p>Chemotherapy-induced nausea and vomiting are among the most distressing side effects of cancer therapy. Younger age is a risk factor for chemotherapy-induced nausea and vomiting, and cancer incidence is rising among young adults ages 18-39 years. However, the comparative burden of chemotherapy-induced nausea and vomiting in young adults vs non-young adults remains insufficiently understood. This study compared acute and delayed chemotherapy-induced nausea and vomiting between young adults and non-young adults (ie, ages 40 years and older) after the first infusion of moderately or highly emetogenic chemotherapy. Of 1609 participants, 159 (10%) were young adults. Rates of guideline-consistent antiemetic prophylactic care were similar between groups (65% young adults, 71% non-young adults; P = .11). Despite this, acute nausea was more prevalent (69% vs 40%; P < .001) and severe (mean [SD] = 3.9 [2.6] vs mean = 3.0 [2.3] on 0-10 scale; P < .001) among young adults vs non-young adults. Similarly, delayed nausea was more prevalent (85% vs 69%; P < .001) and severe (mean = 4.5 [2.4] vs mean = 3.7 [2.5]; P < .001) among young adults. Findings may inform clinical approaches to managing chemotherapy-induced nausea and vomiting among young adults.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic risk stratification of common diseases in breast cancer survivors: a population-based cohort study.","authors":"Annabelle Ashworth, Zhuqing Shi, Huy Tran, Jun Wei, Ashley J Mulford, Siqun Lilly Zheng, David Duggan, Brian T Helfand, Alan R Sanders, Tariq Azam, Bruce Brockstein, Allison DePersia, Poornima Saha, Jianfeng Xu, Ted A James","doi":"10.1093/jncics/pkag089","DOIUrl":"10.1093/jncics/pkag089","url":null,"abstract":"<p><strong>Background: </strong>Patients diagnosed with breast cancer are at increased risk of multiple common diseases; however, the spectrum of these diseases and the contribution of inherited genetic susceptibility remain incompletely characterized.</p><p><strong>Methods: </strong>We evaluated 15 common diseases and tested their associations with breast cancer exposure and disease-specific polygenic risk scores in the UK Biobank (n = 254 736). Analyses were performed using cause-specific Cox proportional hazards models within a full-cohort framework, with time-updated breast cancer status, delayed entry at study recruitment, and age as the underlying time scale.</p><p><strong>Results: </strong>After recruitment, incident breast cancer was diagnosed in 11 386 women (4.47%), including 2742 (24.08%) with metastatic breast cancer. Patients with breast cancer had an increased risk of 9 diseases spanning cardiovascular, metabolic, and neuropsychiatric domains (P < .003, Bonferroni corrected). Elevated risks were generally observed among patients with both early-stage and advanced breast cancer. Inherited susceptibility further stratified disease risk, with the highest risks observed among patients with breast cancer and elevated disease-specific polygenic risk scores. For example, compared with women without breast cancer, the hazard ratio for osteoporosis was 2.33 (95% CI = 2.15 to 2.52) among women with any breast cancer, 2.38 (95% CI = 2.18 to 2.59) among women with nonmetastatic breast cancer, and 2.12 (95% CI = 1.78 to 2.54) among women with metastatic breast cancer; the hazard ratio was 4.48 (95% CI = 3.99 to 5.02) among patients with breast cancer in the highest quartile of osteoporosis-specific polygenic risk scores (all P < .001). In contrast, breast cancer was not statistically significantly associated with risk of coronary artery disease.</p><p><strong>Conclusion: </strong>Breast cancer and inherited genetic susceptibility jointly contribute to increased risk of multiple common diseases, supporting the integration of genetic risk stratification into survivorship care.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative analysis prioritizes proteins associated with renal cell carcinoma and its risk factors.","authors":"Ibrahim Hossain Sajal, Andrew J Song, Kevin M Brown, Mitchell J Machiela, Peter Kraft, Stephen Chanock, Mark P Purdue, Diptavo Dutta","doi":"10.1093/jncics/pkag074","DOIUrl":"10.1093/jncics/pkag074","url":null,"abstract":"<p><strong>Background: </strong>Renal cell carcinoma (RCC), the predominant form of kidney cancer, is influenced by several risk factors, including obesity, hypertension, and smoking. The molecular mechanisms linking these risk factors to RCC, however, remain unclear.</p><p><strong>Methods: </strong>We investigated plasma proteins as potential intermediates of the effects of risk factors on RCC using 2-step mendelian randomization. In step 1, we identified plasma proteins influenced by each risk factor, using genome-wide association study summary statistics from the UK Biobank Proteomics (n = 34 557) for plasma proteins and 19 risk factors encompassing anthropometric traits, blood pressure, smoking behavior, blood cell counts, and kidney function. In step 2, we evaluated the effects of these risk factor-associated plasma proteins on RCC, using the largest-to-date RCC genome-wide association study (29 020 cases). Proteins strongly associated both with risk factors and with RCC were further prioritized through convergent evidence from multiple downstream analyses.</p><p><strong>Results: </strong>Among 2940 plasma proteins, 2339 were statistically significantly associated (P < 1.7×10-05) with at least 1 of the 19 risk factors. Of these 2339 proteins, 33 showed a statistically significant effect on RCC (false discovery rate < 5%), with 28 mapping outside RCC genome-wide association study loci. Using multivariable mendelian randomized, we estimated the mediation effects of associated plasma proteins, finding that proteins such as APOL1 mediated 2.76% of white blood cells' effect. Convergent evidence from multiple downstream analyses prioritized TYMP, UMOD, and USP28 as key protein intermediaries of the risk factor effects on RCC. TYMP and USP28, both inversely associated with RCC risk, showed immune-related and tumor-suppressive effects, while UMOD was positively associated, potentially linking kidney biomarkers to carcinogenesis.</p><p><strong>Conclusions: </strong>Our analysis highlights plasma proteins as intermediates of the effect of distinct risk factors on RCC, thereby nominating molecular targets for further investigation.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing and prognosis of brain metastasis development in breast cancer by subtype.","authors":"Narmeen S Rashid, Nayan Lamba, Ivy Ricca, Marciana Johnson, Paul J Catalano, Shyam K Tanguturi, Rifaquat Rahman, Daphne A Haas-Kogan, Patrick Y Wen, Sarah L Sammons, Nancy U Lin, Ayal A Aizer","doi":"10.1093/jncics/pkag098","DOIUrl":"10.1093/jncics/pkag098","url":null,"abstract":"<p><p>Limited data on the timing of brain metastases development and subsequent prognosis by breast cancer subtype exist. We retrospectively evaluated a cohort of 671 patients diagnosed with brain metastases secondary to breast cancer. Patients were categorized by subtype: human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-positive/HER2-negative (HR+/HER2-), and triple negative (TN). We found significant heterogeneity in the timing of brain metastases development and subsequent prognosis by subtype. Patients with HR+/HER2- disease developed brain metastases later in the disease course compared to patients with HER2+ and TN disease. Median overall survival (OS) following the diagnosis of brain metastases was shortest in patients with TN disease; however, among all subtypes, OS decreased with an increasing number of systemic therapies received before the diagnosis of brain metastases. Altogether, these findings may inform differential timing of brain-directed screening imaging in patients with breast cancer.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13661005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of liquid biopsy screening for gastric cancer in the United States.","authors":"Jeong Yun Yang, Alice Agyekum, Kevin J Rouse, Sheila D Rustgi, Chin Hur","doi":"10.1093/jncics/pkag090","DOIUrl":"10.1093/jncics/pkag090","url":null,"abstract":"<p><strong>Background: </strong>Despite the frequent late-stage diagnosis of gastric cancer (GC), the United States lacks a routine GC screening program. Liquid biopsy (LB), specifically blood-based tests, has emerged as a potential screening approach, but it is unclear whether such a strategy is cost-effective. We, therefore, evaluated the cost-effectiveness of LB screening for GC in the United States.</p><p><strong>Methods: </strong>A Markov model was developed to compare no screening (current standard-of-care) and 2 LB-screening strategies. The study used a simulated cohort of 45-year-old individuals with average risk of GC. Primary model outcomes included life expectancy, quality-adjusted life-years (QALYs), total cost, and incremental cost-effectiveness ratios (ICERs). A strategy was considered cost-effective if the ICER was < the US willingness-to-pay threshold of $100 000 per quality-adjusted-life-year gained.</p><p><strong>Results: </strong>In the base-case analysis, LB screening strategies were not cost-effective, with an ICER of $917 826 per QALY gained. Screening became cost-effective for high-risk subpopulations or when the per-test cost was approximately $89.</p><p><strong>Conclusions: </strong>This economic evaluation of LB for GC screening found that while LB strategies are effective in reducing cancer incidence and mortality, they are not cost-effective due to high test costs. Our findings could help inform the potential planning of future clinical validation studies for LB tests used for GC screening.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13651692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of cancer characteristics with disability status and timing of onset among working-age cancer survivors.","authors":"Hyo Jung Tak, Ya-Chen Tina Shih, Brandon L Grimm, Andrew M Goldsweig, Min Sok Lee, Ronnie D Horner","doi":"10.1093/jncics/pkag091","DOIUrl":"10.1093/jncics/pkag091","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies examine the impact of cancer and disability on health-care use, financial toxicity, and health outcomes but not the relationship between cancer and disability. This study investigates whether and how cancer characteristics are associated with disability status (Social Security Disability Insurance) and timing of onset among prime working-age cancer survivors.</p><p><strong>Methods: </strong>We used the 1999 to 2022 Surveillance, Epidemiology, and End Results file linked with Medicare data. Outcome was a categorical variable indicating no disability, disability onset ≥2 years and 0-<2 years before cancer diagnosis, and 0-<2 years and ≥2 years after diagnosis. Primary independent variables were 16 categories of cancer sites and stage at diagnosis. We employed a multivariable multinomial probit regression model, adjusting for patient and neighborhood characteristics, overall and by 5-year survival.</p><p><strong>Results: </strong>Of the total sample (n = 97 642), 62.2%, 22.4%, and 15.4% had no, precancer, and postcancer disability, respectively. Likelihood of disability and timing of disability onset differed by cancer sites. Compared with prostate cancer survivors (lowest prevalence of disability), adjusted predicted probability of having disability ≥2 years before diagnosis was higher by 0.46 (95% CI = 0.43 to 0.49) among liver cancer survivors, whereas having disability <2 years after diagnosis was higher by 0.29 (95% CI = 0.27 to 0.32) among brain cancer survivors. Nearly all <5-year cancer survivors had disability, and the patterns of association varied significantly by 5-year survival.</p><p><strong>Conclusions: </strong>Clinically assessed disability is strongly associated with specific cancer sites. These findings may point to strategies to improve efficiency of cancer prevention and care, reducing untoward impacts on survival.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Race, ethnicity, and prior colorectal screening test use in CONFIRM colonoscopy vs fecal immunochemical testing trial participants.","authors":"Douglas J Robertson, Jason A Dominitz, Alexander Beed, Kathy Boardman, Barbara J Del Curto, Peter D Guarino, Grant D Huang, Thomas F Imperiale, Andrew LaCasse, Meaghan Larson, Samir Gupta, David Lieberman, Beata Planeta, Timothy J O'Leary, Aasma Shaukat, Shanaz Sultan, Tassos C Kyriakides","doi":"10.1093/jncics/pkag080","DOIUrl":"10.1093/jncics/pkag080","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) outcomes vary by race and ethnicity, and screening test use may contribute to this variation. We examined the association of race, ethnicity, and associated factors with CRC screening test use in a setting where financial barriers to screening are mitigated.</p><p><strong>Methods: </strong>Survey information was gathered from US veteran participants (n = 50 125) when enrolled into a randomized trial comparing screening colonoscopy to annual fecal immunochemical testing in the prevention of CRC mortality. The primary exposures of interest were the participants' self-identified race and ethnicity, with adjustment for variables capturing access to care. Multivariable logistic regression, stratified by site and age, was used to assess the relationship between exposures of interest and prior use of any CRC screening test, prior colonoscopy, and prior fecal occult blood test (including fecal immunochemical testing) use.</p><p><strong>Results: </strong>Screening test use was common (n = 28 330 [56.5%]), with more veterans reporting prior fecal occult blood testing (n = 20 386 [40.7%]) than prior colonoscopy (n = 12 671 [25.3%]). In multivariable analysis, Black participants were more likely (odds ratio [OR] = 1.06, 95% confidence interval [CI] = 1.01 to 1.12) to have had any prior screening relative to White persons, and this finding was driven by more frequent fecal occult blood testing use relative to White persons (OR = 1.16, 95% CI = 1.10 to 1.23). There was no association between Hispanic ethnicity (relative to White persons) on the primary outcomes.</p><p><strong>Conclusions: </strong>In this cohort, prior screening test use was common, with observed variation in overall test use by race, but not ethnicity. Further study of CRC screening test use in diverse populations is needed.</p><p><strong>Clinicaltrials.gov id: </strong>NCT#05612347 (https://clinicaltrials.gov/study/NCT05612347).</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13597112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.","authors":"Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis, Jennifer Ligibel, Paul M Stos, Lois E Shepherd, Wendy R Parulekar, Vuk Stambolic","doi":"10.1093/jncics/pkag068","DOIUrl":"10.1093/jncics/pkag068","url":null,"abstract":"<p><strong>Background: </strong>Circulating levels of cancer antigen (CA) 15-3 have been associated with distant breast cancer recurrence; data on breast cancer subtypes are sparse. We examined associations of CA 15-3 with outcomes across immunohistochemically defined breast cancer subtypes in MA.32.</p><p><strong>Methods: </strong>A total of 3649 participants with T1-3, N0-1, M0 breast cancer were randomly assigned; 2740 (75.1%) provided blood at entry (mean = 278 days postdiagnosis) and 6 months later. Prognostic associations of baseline and 6-month change in CA 15-3 with distant recurrence-free survival (RFS) were examined in luminal (estrogen receptor-positive and/or progesterone receptor-positive, HER2-negative), triple-negative (estrogen receptor, progesterone receptor, HER2 negative) and HER2-positive (any estrogen receptor, progesterone receptor) breast cancer using Cox proportional hazards models.</p><p><strong>Results: </strong>Mean age was 52 years. Breast cancer was luminal in 1589 (58.7%), triple negative in 655 (24.2%), and HER2 positive in 464 (17.1%) participants. Median follow-up was 96 months. CA 15-3 at study entry was not associated with outcome in any subtype. Rising CA 15-3 at 6 months was associated with poor distant RFS in luminal and triple-negative breast cancer (hazard ratio [HR] per 25% increase = 1.41, P < .0001, and HR = 1.35, P < .0001, respectively). New elevations in CA 15-3 at 6 months were adversely associated with distant RFS in those with luminal or triple-negative breast cancer (HR = 4.14, 95% CI = 2.69 to 6.38; P < .001; and HR = 3.57, 95% CI = 1.59 to 7.99; P = .002, respectively). In HER2-positive breast cancer, CA15-3 was not associated with distant RFS.</p><p><strong>Conclusion: </strong>Rising CA 15-3 was associated with reduced distant RFS in luminal and triple-negative breast cancer but not in HER2-positive breast cancer.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov NCT01101438.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148338670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of online cancer information for Aboriginal and Torres Strait Islander peoples: a systematic environmental scan.","authors":"Chloé Maxwell-Smith, Daniela E Iazzi, Cally Jetta, Gail Garvey, Mandy Basson, Haryana M Dhillon, Georgia K B Halkett","doi":"10.1093/jncics/pkag077","DOIUrl":"10.1093/jncics/pkag077","url":null,"abstract":"<p><strong>Background: </strong>Aboriginal and Torres Strait Islander peoples experience greater cancer incidence rates, unmet information needs, and poorer cancer outcomes compared to the general Australian population. This environmental scan evaluated cancer websites for Aboriginal and Torres Strait Islander peoples in Australia.</p><p><strong>Methods: </strong>An environmental scan using 8 Google searches was conducted in July 2025 to identify cancer-related websites targeted toward Aboriginal and Torres Strait Islander peoples in Australia. Patient-facing resources were assessed for readability, understandability, and actionability using grade level assessments of readability and the Patient Education Materials Assessment Tool. Cultural relevance was assessed using an Aboriginal cultural relevance measure.</p><p><strong>Results: </strong>Of 239 search results, 12 websites were patient facing and contained material for Aboriginal and Torres Strait Islander readers, primarily on common cancers. Readability generally exceeded the recommended Grade 6 reading level, with only one resource below Grade 6 level. Resources were considered understandable with scores of >80% for 7/12 websites (range 50-100%); 2/12 included summaries and 7/12 plain language. Actionability scores ranged from 0% to 100% (M = 63.6%, SD = 37.0), with wide variation. Cultural relevance averaged 3.8/7 (SD = 1.9) with only one resource meeting all criteria (7/7). Most lacked cultural specificity and did not provide Aboriginal and Torres Strait Islander languages translations.</p><p><strong>Conclusion: </strong>Our results necessitate co-design with Aboriginal and Torres Strait Islander peoples for resources appropriate to community needs and including information on a broad range of cancers. Websites should optimize the readability and cultural safety of information for Aboriginal and Torres Strait Islander peoples seeking cancer information.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intake of ultra-processed foods and accelerated epigenetic aging of colorectal tissues.","authors":"Matthew A Devall, Hania M Taha, Nadine Khalil, Xiangqing Sun, Gaizun Hu, Alexa Ramirez, Fatima Z Habib, Samyukta Venkatesh, Mourad W Ali, Joseph Willis, Gregory Cooper, Li Li","doi":"10.1093/jncics/pkag092","DOIUrl":"10.1093/jncics/pkag092","url":null,"abstract":"<p><strong>Background: </strong>Ultra-processed food (UPF) intake is associated with colorectal cancer (CRC) risk and may contribute to rising early-onset CRC incidence, although underlying mechanisms remain unclear.</p><p><strong>Methods: </strong>We examined associations between UPF intake and accelerated epigenetic aging (AgeAccel) in normal colorectal tissues among 106 participants (73 African American (AA); 33 European American) in the Cleveland Colon Screening and Risk Factors Study (2012-2018). Ultra-processed food intake was assessed using a Food Frequency Questionnaire and classified according to the NOVA system. AgeAccel was derived from DNA methylation assays of colorectal biopsies. Linear mixed-effects regression models adjusted for energy intake, race, and colorectal location assessed associations.</p><p><strong>Results: </strong>Higher UPF intake was significantly associated with increased AgeAccel in overall colorectum (P = 6.87 × 10-03; β = .061; SE = 0.028), corresponding to a + 1.41-year difference between the highest and lowest quartiles. Associations were significant in the right colon and among AA participants (P < .05).</p><p><strong>Conclusion: </strong>These findings suggest a potential mechanistic link between UPF intake and CRC risk.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13637630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}